Combotope Antibody Libraries for Cancer Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating monoclonal antibodies targeting Tn and STn antigens are laborious, time-consuming, and often lack specificity, as they primarily focus on carbohydrate epitopes without considering the associated peptide/protein carriers, which are crucial for effective cancer therapy and diagnostics.
Innovation Solution
Development of combotope antibodies using phage display technology, where the VH domain specifically binds Tn or STn carbohydrate epitopes and the VL domain recognizes the associated peptide epitopes, creating antibodies with high specificity and affinity for cancer cell targets like MUC1 and CD43.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional monoclonal antibody methods are used to generate antibodies targeting Tn and STn antigens, then antibody production is achieved, but the process is laborious, time-consuming, and lacks specificity
Solution Approach 1:
The antibody is divided into two functional domains: the VH domain that specifically binds Tn or STn carbohydrate epitopes, and the VL domain that recognizes associated peptide epitopes. This segmentation allows independent optimization of each domain's binding properties, enabling rapid generation of specific antibodies through phage display technology without the time-consuming traditional hybridoma methods
Solution Approach 2:
The combotope antibody design creates a universal platform where the VH domain provides carbohydrate epitope recognition while the VL domain provides peptide epitope recognition. This multi-functional antibody structure can be applied to various Tn and STn antigens across different cancer types, eliminating the need to develop entirely new antibodies for each target and significantly reducing development time
2Reliability
If antibodies focus only on carbohydrate epitopes, then simplicity is maintained, but specificity and binding efficiency are insufficient
Solution Approach 1:
The invention merges two binding specificities into a single antibody molecule: the VH domain binds the Tn or STn carbohydrate epitope while the VL domain binds the associated peptide epitope. This combination creates combotope antibodies with enhanced binding efficiency and specificity, as the dual-recognition mechanism ensures high-affinity binding to the complete antigen structure rather than just the carbohydrate portion
Data Source
AI summary
The invention provides specific Tn- and/or STn antibody libraries and methods for identifying specific antibodies, which target Tn- and/or STn-glycosylation sites of any glycoprotein of choice, especially glycoproteins of cancer cell targets. The invention further provides antibodies identified by the new concept proposed herein, which have combined specificity towards both the sugar epitope as well as the peptide epitope of the glycoprotein.